COVID-19 and MOG-IgG–associated acquired demyelinating polyneuropathy compatible with chronic inflammatory demyelinating polyneuropathy in a previously healthy girl. Issue 5 (15th September 2022)

• Record Type: Journal Article
• Authors: Akbar, Asra; Blume, Gregory M.; Creeden, Sean; Ahmad, Sharjeel
• Is Part Of: Proceedings. Volume 35:Issue 5(2022)
• Page Start: 719
• Page End: 721
• Publication Date: 2022-09-15
• Subjects: Acquired neuropathy -- acute disseminating encephalomyelitis -- chronic inflammatory demyelinating polyneuropathy -- COVID-19 -- Guillain-Barré syndrome -- MOG-IgG antibody -- SARS-CoV2; Medicine -- Periodicals; Medicine; Medicine -- Periodicals; Periodicals; Electronic journals; 616.005
• DOI: 10.1080/08998280.2022.2088466
• Languages: English
• ISSNs: 0899-8280

Abstract

Abstract: Neurological manifestations of COVID-19 in the pediatric population are not as well described as those in the adult population. We describe a case of myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG)–associated disorder in a 9-year-old girl, who experienced complete recovery. This rare disorder is a demyelinating disease that often relapses and has the potential to cause severe morbidity. The case highlights the need for early recognition of asymptomatic and subacute presentations of demyelinating disorders and testing for MOG-IgG antibodies, as the management of presumed monophasic demyelinating disorders vs MOG-IgG–positive demyelinating disorder is different.